Cystinuria Pipeline Insight
DelveInsight’s, “Cystinuria - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cystinuria is a rare genetic disorder that causes a buildup of an amino acid called cystine in the urine. This can result in the formation of cystine kidney stones. Cystine stones are often larger, harder and form more frequently than other kinds of kidney stones. Due to the larger stone size, cystine stones may be more difficult to pass, often requiring surgical procedures to remove. Stones can create blockages in the urinary tract and reduce the ability of the kidneys to eliminate waste through urine. The stones also provide sites where bacteria may cause infections. Signs and symptoms of the condition are related to the presence of stones and may include blood in the urine, flank pain, and frequent urinary tract infections.
"Cystinuria - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cystinuria pipeline landscape is provided which includes the disease overview and Cystinuria treatment guidelines. The assessment part of the report embraces, in depth Cystinuria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystinuria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Cystinuria R&D. The therapies under development are focused on novel approaches to treat/improve Cystinuria.
Cystinuria Emerging Drugs Chapters
This segment of the Cystinuria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cystinuria Emerging Drugs
Bucillamine: Revive Therapeutics
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection. The drug is in phase 2 of clinical trials for the treatment of cystinuria.
ADV 7103: Advicenne
ADV7103 is an investigational drug and has not yet been approved by any regulatory authority and is being developed by Advicenne. Advicenne Received Positive CHMP Opinion Recommending Approval of ADV7103 for the Treatment of Distal Renal Tubular Acidosis (dRTA). The drug is in phase II/III of clinical trials for the treatment of cystinuria.
Further product details are provided in the report……..
Cystinuria: Therapeutic Assessment
This segment of the report provides insights about the different Cystinuria drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cystinuria
There are approx. 3+ key companies which are developing the therapies for Cystinuria. The companies which have their Cystinuria drug candidates in the mid to advanced stage, i.e. phase II/III include, Advicenne and others.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
- Late-stage products (phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Cystinuria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cystinuria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystinuria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystinuria drugs.
Cystinuria Report Insights
- Cystinuria Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cystinuria Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cystinuria drugs?
- How many Cystinuria drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cystinuria?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cystinuria therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cystinuria and their status?
- What are the key designations that have been granted to the emerging drugs?